Kodiak Sciences (BMV:KOD *) - Aandelenkoers, Nieuws & Analyse

KOD * Overzicht aandelen

A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Over het bedrijf

KOD * fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Kodiak Sciences Inc. Concurrenten

Genomma Lab Internacional. de

BMV:LAB B

Mex$23.2b

Amarin

NasdaqGM:AMRN

US$238.5m

Cabaletta Bio

NasdaqGS:CABA

US$239.6m

Sensorion

ENXTPA:ALSEN

€219.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Kodiak Sciences
Historische aandelenkoersen
Huidige aandelenkoers	US$148.04
52 Week Hoogtepunt	US$205.00
52 Week Laag	US$160.13
Bèta	1.77
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-89.12%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	KOD *	MX Biotechs	MX Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe KOD * presteerde ten opzichte van de MX Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe KOD * presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is KOD *'s price volatile compared to industry and market?
KOD * volatility
KOD * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiele aandelenkoers: KOD * heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van KOD * in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	112	Victor Perlroth	kodiak.com

Kodiak Sciences Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Kodiak Sciences zich tot de beurswaarde?
KOD * fundamentele statistieken
Marktkapitalisatie	Mex$4.32b
Inkomsten(TTM)	-Mex$6.03b
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.7x

Koers/Winstverhouding

Is KOD * overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
KOD * resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$333.82m
Inkomsten	-US$333.82m

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-6.41
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde KOD * op de lange termijn?

Bekijk historische prestaties en vergelijking

KOD * Overzicht aandelen

Beloningen

Risicoanalyse

Kodiak Sciences Inc. Concurrenten

BMV:LAB B

Mex$23.2b

NasdaqGM:AMRN

US$238.5m

NasdaqGS:CABA

US$239.6m

ENXTPA:ALSEN

€219.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Kodiak Sciences Inc. Announces Executive Appointments

Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Inc., Annual General Meeting, Jun 04, 2024

Kodiak Sciences Inc. to Report Q4, 2023 Results on Mar 28, 2024

Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting

Recent updates

Kodiak Sciences Inc. Announces Executive Appointments

Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Inc., Annual General Meeting, Jun 04, 2024

Kodiak Sciences Inc. to Report Q4, 2023 Results on Mar 28, 2024

Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting

Kokak Sciences Inc. Announces Top-Line, One-Year Results for Its ABC Platform Based Investigational Therapy Tarcocimab Tedromer 5 Mg from the Pivotal Beacon Study

Jason Ehrlich, M.D., Ph.D., Informs Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Jason Ehrlich, M.D., Ph.D., Informes Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

Kodiak Sciences Reports Positive Topline Results from Beacon Phase 3 Study of Tarcocimab Tedromer (Ksi-301) in Patients with Retinal Vein Occlusion

Kodiak Sciences Inc. Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from Russell 2000 Growth Index

Co-Founder recently sold Mex$251m worth of stock

Kodiak Sciences Inc. Announces Top-Line Results from Its Initial Phase 2B/3 Study of KSI-301 in Patients with Neovascular Age-Related Macular Degeneration

Kodiak Sciences Inc. Completes Enrollment in Gleam and Glimmer Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

Kodiak Sciences Inc. Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

Forecast to breakeven in 2025

Forecast to breakeven in 2024

Kodiak Sciences Inc. Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1B Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting

Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences Inc. to Report Q3, 2020 Results on Nov 09, 2020

Kodiak Sciences Inc. Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Kodiak Sciences Inc. Samenvatting

0.0x

-0.7x

Inkomsten en omzet